SI9300614A - Atovaquone and proguanil combinations - Google Patents

Atovaquone and proguanil combinations Download PDF

Info

Publication number
SI9300614A
SI9300614A SI9300614A SI9300614A SI9300614A SI 9300614 A SI9300614 A SI 9300614A SI 9300614 A SI9300614 A SI 9300614A SI 9300614 A SI9300614 A SI 9300614A SI 9300614 A SI9300614 A SI 9300614A
Authority
SI
Slovenia
Prior art keywords
chlorophenyl
atovaquone
naphthoquinone
progvanil
cyclohexyl
Prior art date
Application number
SI9300614A
Other languages
English (en)
Slovenian (sl)
Inventor
Winston Edward Gutteridge
David Brian Ashton Hutchinson
Victoria Susan Latter
Mary Pudney
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10725687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9300614(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SI9300614A publication Critical patent/SI9300614A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9300614A 1992-11-26 1993-11-25 Atovaquone and proguanil combinations SI9300614A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929224739A GB9224739D0 (en) 1992-11-26 1992-11-26 Medicaments

Publications (1)

Publication Number Publication Date
SI9300614A true SI9300614A (en) 1994-06-30

Family

ID=10725687

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300614A SI9300614A (en) 1992-11-26 1993-11-25 Atovaquone and proguanil combinations

Country Status (38)

Country Link
US (3) US5998449A (ro)
EP (1) EP0670719B1 (ro)
JP (1) JP3768231B2 (ro)
KR (1) KR100294802B1 (ro)
CN (1) CN1087935C (ro)
AP (1) AP517A (ro)
AT (1) ATE191340T1 (ro)
AU (1) AU685408B2 (ro)
BG (1) BG62595B1 (ro)
CA (1) CA2150234E (ro)
CY (1) CY2193B1 (ro)
CZ (2) CZ289171B6 (ro)
DE (1) DE69328307T2 (ro)
DK (1) DK0670719T3 (ro)
ES (1) ES2145114T3 (ro)
GB (1) GB9224739D0 (ro)
GR (1) GR3033745T3 (ro)
HK (1) HK1004468A1 (ro)
HU (1) HU225918B1 (ro)
IL (1) IL107755A (ro)
MX (1) MX9307402A (ro)
MY (1) MY114241A (ro)
NO (1) NO313225B1 (ro)
NZ (1) NZ257901A (ro)
OA (1) OA10352A (ro)
PE (1) PE55694A1 (ro)
PL (1) PL174323B1 (ro)
PT (1) PT670719E (ro)
RO (1) RO119280B1 (ro)
RU (1) RU2108092C1 (ro)
SA (1) SA93140434B1 (ro)
SG (1) SG45387A1 (ro)
SI (1) SI9300614A (ro)
SK (1) SK281559B6 (ro)
TW (1) TW253835B (ro)
UA (1) UA45948C2 (ro)
WO (1) WO1994012164A1 (ro)
ZA (1) ZA938832B (ro)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9424013D0 (en) * 1994-11-29 1995-01-18 Wellcome Found Medicaments
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
GB9822681D0 (en) * 1998-10-16 1998-12-09 Vitabiotics Ltd Method of treatment
CZ294903B6 (cs) * 1999-04-09 2005-04-13 Glaxo Group Limited Kombinační prostředek pro léčení malárie
US7104076B2 (en) * 2004-06-24 2006-09-12 Carrier Corporation Lubricant return schemes for use in refrigerant cycle
ITMI20070941A1 (it) * 2007-05-09 2008-11-10 Chimico Internazi0Nale S P A L Procedimento per la preparazione di naftochinoni trans2,3-disostituiti
EP2467358B1 (en) * 2009-08-20 2014-07-23 IPCA Laboratories Limited Novel complex for treatment and/or prophylaxis of parasitic infections
US20180055835A1 (en) 2016-08-25 2018-03-01 Immune Therapeutics Inc. Method for Treating And Preventing Protozoal Infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533648A (en) * 1949-03-05 1950-12-12 Joseph H Warburg Circular saw making
NL6411993A (ro) * 1963-10-18 1965-04-20
US3347830A (en) * 1964-07-30 1967-10-17 Grace W R & Co Process of polymerizing formaldehyde
GB1141735A (en) * 1966-11-23 1969-01-29 Pfizer & Co C Pharmaceutical anti-tumor composition
NL6817526A (ro) * 1968-01-24 1969-07-28
US3655699A (en) * 1970-03-02 1972-04-11 Pfizer Analogues of lapachol as antitumor agents
DE2601458A1 (de) * 1975-01-20 1976-07-22 Ciba Geigy Ag Loesliche, von phenylindandiaminen abgeleitete polyamide
EP0002228B1 (en) * 1977-11-22 1984-02-29 The Wellcome Foundation Limited Hydroxy naphthoquinone derivatives, their preparations for treating and preventing theileriosis in cattle and sheep, processes for their synthesis; naphthoquinone derivatives
US4485116A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
US4485117A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
GB8310141D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Naphthoquinone derivatives
GB8310140D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Antiprotozoal agents
JPS59196467A (ja) * 1983-04-23 1984-11-07 Nissan Motor Co Ltd 車輪速及びまたは車輪加減速度検出方法
US5225184A (en) * 1988-08-16 1993-07-06 Burroughs Wellcome Co. Medicaments
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
HU208624B (en) * 1988-08-16 1993-12-28 Wellcome Found Process for producing pharmaceutical compositions containing naphtoquinone derivatives effective against pneumocystis infections
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
GB8921516D0 (en) * 1989-09-22 1989-11-08 Wellcome Found Medicaments
GB8923254D0 (en) * 1989-10-16 1989-12-06 Wellcome Found Medicaments
US5014737A (en) * 1989-11-13 1991-05-14 Allan Berman Quartz integrated trough/sump recirculating filtered high-purity chemical bath
GB9121316D0 (en) * 1991-10-09 1991-11-20 Wellcome Found Heterocyclic compounds
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
US5529994A (en) * 1993-05-05 1996-06-25 Palo Alto Medical Foundation Treatment for toxoplasmosis
DE69400631T2 (de) * 1993-05-05 1997-02-27 Palo Alto Medical Foundation, Palo Alto, Calif. Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose
US5733932A (en) * 1995-01-06 1998-03-31 The Picower Institute For Medical Research Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
US5827543A (en) * 1995-12-07 1998-10-27 The Procter & Gamble Company Methods and compositions for the prevention and treatment of urogenital disorders
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US5747476A (en) * 1996-07-17 1998-05-05 Mortar & Pestle Veterinary Pharmacy, Inc. Treatment of equine protozoal myeloencephalitis
ZA983331B (en) * 1997-05-01 1998-10-27 Allegheny University Of The He Method for treating protozoal infections
AUPO821097A0 (en) * 1997-07-25 1997-08-14 Cultor Ltd. A prophylactic
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
CZ294903B6 (cs) * 1999-04-09 2005-04-13 Glaxo Group Limited Kombinační prostředek pro léčení malárie

Also Published As

Publication number Publication date
OA10352A (en) 2001-10-22
MX9307402A (es) 1994-07-29
RO119280B1 (ro) 2004-07-30
UA45948C2 (uk) 2002-05-15
AP9300592A0 (en) 1994-01-31
US6166046A (en) 2000-12-26
CY2193B1 (en) 2002-11-08
NO951995D0 (no) 1995-05-19
BG99656A (bg) 1996-04-30
AU685408B2 (en) 1998-01-22
CA2150234A1 (en) 1994-06-09
SG45387A1 (en) 1998-01-16
HU225918B1 (en) 2007-12-28
SK57095A3 (en) 1996-05-08
SK281559B6 (sk) 2001-05-10
US5998449A (en) 1999-12-07
PT670719E (pt) 2000-09-29
CZ289692B6 (cs) 2002-03-13
PL174323B1 (pl) 1998-07-31
PE55694A1 (es) 1995-01-25
RU2108092C1 (ru) 1998-04-10
GR3033745T3 (en) 2000-10-31
JP3768231B2 (ja) 2006-04-19
ZA938832B (en) 1995-05-25
CZ289171B6 (cs) 2001-11-14
CA2150234C (en) 2001-01-16
CN1087935C (zh) 2002-07-24
AP517A (en) 1996-08-23
GB9224739D0 (en) 1993-01-13
DE69328307D1 (de) 2000-05-11
TW253835B (ro) 1995-08-11
AU5532294A (en) 1994-06-22
JPH08503938A (ja) 1996-04-30
DK0670719T3 (da) 2000-07-31
CZ119295A3 (en) 1995-11-15
CA2150234E (en) 2005-03-22
KR100294802B1 (ko) 2001-09-17
HU9501537D0 (en) 1995-07-28
SA93140434B1 (ar) 2004-09-01
ATE191340T1 (de) 2000-04-15
HUT71346A (en) 1995-11-28
IL107755A0 (en) 1994-02-27
ES2145114T3 (es) 2000-07-01
PL309222A1 (en) 1995-10-02
DE69328307T2 (de) 2000-10-26
NZ257901A (en) 1997-01-29
CN1091632A (zh) 1994-09-07
IL107755A (en) 2000-10-31
WO1994012164A1 (en) 1994-06-09
NO313225B1 (no) 2002-09-02
NO951995L (no) 1995-07-03
MY114241A (en) 2002-09-30
EP0670719B1 (en) 2000-04-05
US6291488B1 (en) 2001-09-18
BG62595B1 (bg) 2000-03-31
HK1004468A1 (en) 1998-11-27
EP0670719A1 (en) 1995-09-13

Similar Documents

Publication Publication Date Title
SI9300614A (en) Atovaquone and proguanil combinations
AU629533B2 (en) Improving toxicity profiles in chemotherapy
DE69230790T2 (de) Arzneimittel zur Behandlung von durch Babesia verursachten Protozoeninfektionen
DK175716B1 (da) Anvendelse af en substitueret naphthoquinon eller et derivat deraf til fremstilling af et lægemiddel til behandling af toxoplasmose
DE69312297T2 (de) Verwendung von 2-[4-(-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphtoquinon zur behandlung von krebs
US4818767A (en) Quinate salts of antimalarial phenanthrenemethanol compounds
DE68916443T2 (de) Arzneimittel zur behandlung von kryptosporidiose.
WO2015001799A1 (ja) バベシア症の治療剤及び予防剤
JPH11228422A (ja) 抗マラリア剤
NZ209519A (en) 1--3- aminopropanol derivatives and pharmaceutical compositions
US20240010625A1 (en) Furanic quaternary ammonium salts
US4521424A (en) Quinate salts of the antimalarial compound mefloquine
JPH07505388A (ja) 抗原生動物及び抗寄生虫活性を有する１，４−ナフトキノン誘導体
WO1993023066A1 (en) Platelet growth promoter

Legal Events

Date Code Title Description
IF Valid on the event date